BlueMountain Capital Management LLC Increases Holdings in PTC Therapeutics, Inc. (PTCT)

BlueMountain Capital Management LLC grew its position in PTC Therapeutics, Inc. (NASDAQ:PTCT) by 25.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,402 shares of the biopharmaceutical company’s stock after acquiring an additional 5,355 shares during the quarter. BlueMountain Capital Management LLC owned 0.06% of PTC Therapeutics worth $891,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Xact Kapitalforvaltning AB bought a new stake in shares of PTC Therapeutics in the 2nd quarter worth approximately $216,000. Hussman Strategic Advisors Inc. bought a new position in shares of PTC Therapeutics during the 2nd quarter worth approximately $1,686,000. ClariVest Asset Management LLC bought a new position in shares of PTC Therapeutics during the 2nd quarter worth approximately $2,079,000. State of Wisconsin Investment Board lifted its position in shares of PTC Therapeutics by 68.3% during the 1st quarter. State of Wisconsin Investment Board now owns 40,400 shares of the biopharmaceutical company’s stock worth $1,093,000 after buying an additional 16,400 shares during the period. Finally, Fox Run Management L.L.C. bought a new position in shares of PTC Therapeutics during the 2nd quarter worth approximately $405,000. Institutional investors own 85.48% of the company’s stock.

In related news, EVP Neil Gregory Almstead sold 20,000 shares of the firm’s stock in a transaction on Tuesday, June 19th. The stock was sold at an average price of $48.31, for a total transaction of $966,200.00. Following the completion of the sale, the executive vice president now directly owns 37,154 shares of the company’s stock, valued at approximately $1,794,909.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 7.50% of the company’s stock.

PTCT has been the subject of several analyst reports. Citigroup restated a “buy” rating and set a $50.00 target price (up previously from $35.00) on shares of PTC Therapeutics in a research report on Tuesday, July 24th. ValuEngine upgraded PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 10th. Bank of America raised their target price on PTC Therapeutics from $27.00 to $31.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 31st. Credit Suisse Group raised their target price on PTC Therapeutics from $49.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 5th. Finally, Barclays raised their target price on PTC Therapeutics from $40.00 to $43.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $33.43.

PTC Therapeutics stock opened at $47.77 on Friday. The company has a quick ratio of 4.18, a current ratio of 4.34 and a debt-to-equity ratio of 0.55. The company has a market cap of $2.36 billion, a P/E ratio of -23.65 and a beta of 1.95. PTC Therapeutics, Inc. has a one year low of $14.56 and a one year high of $52.95.

PTC Therapeutics (NASDAQ:PTCT) last released its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.15. PTC Therapeutics had a negative return on equity of 27.41% and a negative net margin of 25.03%. The firm had revenue of $68.74 million during the quarter, compared to analysts’ expectations of $69.83 million. equities research analysts forecast that PTC Therapeutics, Inc. will post -1.48 EPS for the current fiscal year.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.

Recommended Story: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding PTCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PTC Therapeutics, Inc. (NASDAQ:PTCT).

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply